RecruitingPhase 4NCT06875960

A Study to Continue the Administration of Deucravacitinib in Participants With Systemic Lupus Erythematosus (SLE) or Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) Who Have Completed Study IM011074 or Study IM011132

A Continuation Protocol for Deucravacitinib in Patients With Patients With Systemic Lupus Erythematosus (SLE) or Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) Who Have Completed Study IM011074 or Study IM011132

Sponsor

Bristol-Myers Squibb

Enrollment

35 participants

Start Date

Feb 24, 2026

Study Type

INTERVENTIONAL

Conditions

Systemic Lupus Erythematosus (SLE)Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE)

Summary

The purpose of this study is to allow the continued administration of Deucravacitinib in participants with Systemic Lupus Erythematosus (SLE) or Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) who have completed study IM011074 or Study IM011132

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called BMS-986165 for people with discoid and/or subacute cutaneous lupus erythematosus (dle/scle) and systemic lupus erythematosus (sle). The study is currently recruiting participants at 4 locations. People eligible for this study include aged 18 Years to 75 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGBMS-986165

Specified dose on specified days

Locations(4)

Local Institution - 0001

Farmington, Connecticut, United States

New York University School Of Medicine

New York, New York, United States

Oklahoma Medical Research Foundation

Oklahoma City, Oklahoma, United States

Local Institution - 0003

Jackson, Tennessee, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06875960

Related Trials

A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease

NCT0733248113 locations

A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants

NCT0717528565 locations

Safety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine in Autoimmune Rheumatic Diseases

NCT070879122 locations

Double-blind Placebo Controlled Study to Evaluate the Effect of NAD+ Boosting With Nicotinamide Riboside on Immunometabolism and Immunity in Systemic Lupus Erythematosus

NCT060329231 location

INTERSTELLAR - International Study Evaluating Lupus Outcomes After Anifrolumab Real World Use

NCT0631428232 locations